



InVivo Therapeutics to Present at the LD Micro Main Event on Tuesday December 4th, 2018

CAMBRIDGE, Mass. (November 29, 2018) – **InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV)** today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the LD Micro Main Event on Tuesday, December 4, 2018 at 7:30 am Pacific Time at the Luxe Hotel in Los Angeles, CA . Dr. Toselli's presentation will discuss recent company updates. A live webcast of Dr. Toselli's presentation will be available at <http://wsw.com/webcast/ldmicro15/nviv/> and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 minutes before the event to ensure a timely connection. Dr. Toselli will also be available for one-on-one meetings at the conference.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. In January 2018, the company announced updated clinical evidence, including improvements in patients with acute spinal cord injury (SCI), from its INSPIRE study of the *Neuro-Spinal Scaffold*TM. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

CONTACT:

Heather Hamel

(617) 863-5530

Investor Relations

Investor-relations@invivotherapeutics.com